Statement re Update on Hypertension Pilot Programme
February 04 2021 - 2:00AM
Statement re Update on Hypertension Pilot Programme
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Update on Hypertension Pilot
Programme
DXS International plc ("DXS", the "Company"),
the digital clinical decision support Company, is pleased to update
shareholders on its ExpertCare hypertension solution pilot
programme.
Managing patients on medication for hypertension
is complex, exacerbated by the fact that more than 60% of
hypertensives have one or more comorbidity such as Diabetes, Atrial
Fibrillation, or COPD. While UK guidelines on how to treat this
exist, getting the medicines combination and dosages correct for
all hypertensive patients is extremely difficult for busy
clinicians.
DXS has invested five years and over £1.5
million creating ExpertCare which is able to analyse and interpret
a patient’s electronic record and instantly present prescribing
recommendations. There are currently 12 pilots live at various
stages, with a total of 30 pilots planned, each with a minimum of
at least 30 patients in each pilot. Initial results from four
completed pilots in GP practices are encouraging:
- Patient non-compliance with prescribed treatment was reduced
from 41% to 21%;
- Prescribing regimen particularly in patients with comorbidities
improved in 15% of cases;
- The system is seen as intuitive and easy to use;
- Where the system recommended changes to clinician decisions,
these were on closer inspection fully accepted by the relevant
clinicians as correct and indeed needing change; and
- GPs using the ExpertCare system considered that it could
empower nurses and pharmacists to conduct the majority of
hypertension consultations with minimal GP input.
The benefit to GP practices is estimated to be a
potential saving of 330 GP hours for a 9,000-patient practice,
easing the pressure on hard-pressed GPs and worth £25,000 p.a. per
practice based on the pilot group. Extrapolated across the UK, this
equates to £187 million p.a. or the equivalent of 2,000 full time
GPs.
The UK has 10 million diagnosed hypertensive
patients and it is clear that effectively controlling blood
pressure reduces heart attacks, strokes, and kidney disease. Public
Health England estimates that through optimal anti-hypertensive
treatment, 9,000 heart attacks and 14,000 strokes could be
prevented over 3 years. This equates to a saving of £272 million
for the NHS.
Additional pilots are still in progress and DXS
is working closely with NHS stakeholders to complete a global best
of breed hypertension solution that will deliver significant Return
on Investment to healthcare providers, help plug the GP shortage
gap and improve patient outcomes by increasing compliance and
averting unnecessary complications.
Spurred on by the positive UK results, we have
also started planning for pilots in carefully selected markets
outside the UK. Early research and demonstrations to potential
users are encouraging as the same hypertension problems remain, and
potential returns are higher.
David Immelman, Chief Executive of DXS said: “We
are extremely excited and encouraged by these early results and, as
the situation begins to normalise in the UK, we anticipate being
able to expand marketing of the ExpertCare solution throughout the
UK and internationally. We were delighted to gain CE accreditation
for this product and await GPITF (NHS) accreditation which has been
somewhat delayed by COVID. In the meantime, we are continuing our
pilot programme, adding positive enhancements and optimising this
solution.”
The Directors of DXS International plc accept
responsibility for this announcement.
Contacts:
David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
https://www.dxs-systems.co.uk |
|
Corporate
Advisor |
|
City &
Merchant David Papworth |
020 7101 7676 |
Corporate
Broker |
|
Hybridan
LLPClaire Louise Noyce |
020 3764 2341 |
Notes to Editors
About DXS:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively and
which should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Jul 2023 to Jul 2024